8-K Announcements
6Material company update
May 18, 2026·SEC
Material company update
May 15, 2026·SEC
Material company update
May 14, 2026·SEC
Silexion Therapeutics Ltd.(SLXN)Earnings, Financials & Key Ratios
SLXN•NASDAQ
Price updated Jun 19, 2026
AboutSilexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.Show more
- Revenue$0
- EBITDA$12M+192.8%
- Net Income-$12M+27.6%
- EPS (Diluted)-89.60-239.4%
- ROE-457.63%
SLXN Key Insights
Silexion Therapeutics Ltd. (SLXN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Share count reduced 78.7% through buybacks
- ✓Trading at only 0.1x book value
✗Weaknesses
- ✗Profits declining 127.4% over 5 years
- ✗Weak momentum: RS Rating 1 (bottom 1%)
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when SLXN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
SLXN Price & Volume
Silexion Therapeutics Ltd. (SLXN) stock price & volume — 10-year historical chart
Loading chart...
SLXN Growth Metrics
Silexion Therapeutics Ltd. (SLXN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM23.18%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM403.07%
Return on Capital
10 Years-120.92%
5 Years-105.93%
3 Years-173.9%
Last Year612.69%
SLXN Recent Earnings
Silexion Therapeutics Ltd. (SLXN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 2/8 qtrs (29%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.85+34.1%
$1.29
Rev
—
—
Q2 2026
Mar 17, 2026Metric
Actual
Est
EPS
$2.38-103.8%
$1.17
Rev
—
—
Q4 2025
Nov 12, 2025Metric
Actual
Est
EPS
$2.88+15.3%
$3.40
Rev
—
—
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$4.32-37.1%
$3.15
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.85vs $1.29+34.1% | — |
| Q2 2026 | Mar 17, 2026 | $2.38vs $1.17-103.8% | — |
| Q4 2025 | Nov 12, 2025 | $2.88vs $3.40+15.3% | — |
| Q3 2025 | Aug 12, 2025 | $4.32vs $3.15-37.1% | — |
Based on last 8 quarters of dataView full earnings history →
SLXN Peer Comparison
Silexion Therapeutics Ltd. (SLXN) competitors in RNA and Genome Editing Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 SRPT | 1.85B | 17.53 | -2.46 | 15.58% | 2.98% | 4.89% | 0.91 | |
 ARWR | 11.52B | 81.82 | -6706.56 | 232.58% | -48.38% | -55.09% | 0.73 | |
 NTLA | 1.76B | 15.67 | -4.11 | 16.92% | -5.97% | -57.27% | 0.14 | |
 IONS | 12.25B | 74.12 | -31.14 | 33.87% | -30.87% | -58.57% | 5.35 | |
 REGN | 63.37B | 609.94 | 14.70 | 0.99% | 29.65% | 14.32% | 0.09 | |
 MRNA | 25.37B | 63.96 | -8.81 | -39.23% | -143.55% | -36.73% | 0.22 | |
 BEAM | 3.51B | 34.14 | -42.15 | 120.01% | -49.17% | -5.89% | 0.24 | |
 ILMN | 24.6B | 161.93 | 29.71 | -0.78% | 19.43% | 32.84% | 0.94 |
Compare SLXN vs Peers
Silexion Therapeutics Ltd. (SLXN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
SLXN Income Statement
Silexion Therapeutics Ltd. (SLXN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue Growth % | - | - | - | - | - | - | - |
Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 | 6K |
COGS % of Revenue | - | - | - | - | - | - | - |
Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | 0▲ 0% | -6K▲ 0% |
Gross Margin % | - | - | - | - | - | - | - |
Gross Profit Growth % | - | - | - | - | - | - | - |
Operating Expenses | 195.86K | 943.93K | 3.86M | 4.68M | 12.57M | -11.63M | -10.54M |
OpEx % of Revenue | - | - | - | - | - | - | - |
Selling, General & Admin | 195.86K | 943.93K | 577K | 928K | 6.73M | 4.48M | 4.8M |
SG&A % of Revenue | - | - | - | - | - | - | - |
Research & Development | 0 | 0 | 3.23M | 3.71M | 5.82M | 7.14M | 7.92M |
R&D % of Revenue | - | - | - | - | - | - | - |
Other Operating Expenses | 0 | 0 | 57K | 45K | 25K | -23.25M | -997K |
Operating Income | -195.86K▲ 0% | -943.93K▼ 381.9% | -3.86M▼ 308.9% | -4.68M▼ 21.3% | -12.57M▼ 168.6% | 11.63M▲ 192.5% | 10.53M▲ 0% |
Operating Margin % | - | - | - | - | - | - | - |
Operating Income Growth % | - | -381.94% | -308.93% | -21.27% | -168.55% | 192.53% | - |
EBITDA | -195.86K | -755K | -3.8M | -4.64M | -12.55M | 11.65M | 10.54M |
EBITDA Margin % | - | - | - | - | - | - | - |
EBITDA Growth % | - | -285.48% | -403.71% | -21.9% | -170.62% | 192.83% | 182.49% |
D&A (Non-Cash Add-back) | 0 | 0 | 57K | 45K | 25K | 14K | 12K |
EBIT | -195.86K | -755K | -3.38M | -5.07M | -16.5M | -11.9M | -12.9M |
Net Interest Income | 0 | 6.37K | 29K | 144K | -51K | 129K | 177K |
Interest Income | 0 | 6.37K | 114K | 153K | 1K | 142K | 183K |
Interest Expense | 0 | 0 | 85K | 9K | 52K | 13K | 6K |
Other Income/Expense | 0 | 188.72K | 396K | -395K | -3.94M | -23.54M | -23.44M |
Pretax Income | -195.86K▲ 0% | -755.22K▼ 285.6% | -3.46M▼ 358.7% | -5.08M▼ 46.5% | -16.51M▼ 225.2% | -11.91M▲ 27.9% | -12.91M▲ 0% |
Pretax Margin % | - | - | - | - | - | - | - |
Income Tax | 0 | 0 | 24K | 32K | 10K | 3K | 3K |
Effective Tax Rate % | 0% | 0% | -0.69% | -0.63% | -0.06% | -0.03% | -0.02% |
Net Income | -195.86K▲ 0% | -755.22K▼ 285.6% | -3.21M▼ 325.7% | -4.94M▼ 53.7% | -16.44M▼ 232.7% | -11.91M▲ 27.6% | -12.91M▲ 0% |
Net Margin % | - | - | - | - | - | - | - |
Net Income Growth % | - | -285.59% | -325.7% | -53.72% | -232.72% | 27.56% | 23.18% |
Net Income (Continuing) | -195.86K | -755.22K | -3.49M | -5.11M | -16.52M | -11.91M | -12.91M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 3.59M | 3.42M | 0 | 0 | 0 |
EPS (Diluted) | -0.12▲ 0% | -0.46▼ 284.9% | 0.35▲ 176.2% | -44.20▼ 12764.8% | -26.40▲ 40.3% | -89.60▼ 239.4% | -39.96▲ 0% |
EPS Growth % | - | -284.87% | 176.2% | -12764.76% | 40.27% | -239.39% | 403.07% |
EPS (Basic) | -0.12 | -0.46 | 0.35 | -44.20 | -26.40 | -89.60 | - |
Diluted Shares Outstanding | 1.65M | 1.65M | 1.67M | 111.73K | 623.85K | 132.95K | 323.04K |
Basic Shares Outstanding | 1.65M | 1.65M | 1.67M | 111.73K | 623.85K | 132.95K | 323.04K |
Dividend Payout Ratio | - | - | - | - | - | - | - |
SLXN Balance Sheet
Silexion Therapeutics Ltd. (SLXN) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
Total Current Assets | 51.7K | 407.8K | 8.84M | 4.98M | 2.25M | 6.64M | 4.07M |
Cash & Short-Term Investments | 51.7K | 38.94K | 8.26M | 4.59M | 1.19M | 5.99M | 2.41M |
Cash Only | 51.7K | 38.94K | 8.26M | 4.59M | 1.19M | 5.99M | 2.41M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Sales Outstanding | - | - | - | - | - | - | - |
Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 67K | 49K | 97K | 76K | 123K |
Total Non-Current Assets | 77.7K | 115.01M | 494K | 277K | 613K | 578K | 537K |
Property, Plant & Equipment | 0 | 0 | 464K | 247K | 560K | 437K | 403K |
Fixed Asset Turnover | - | - | - | - | - | - | 0.00x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 115.01M | 0 | 0 | 0 | 57K | 168K |
Other Non-Current Assets | 77.7K | 0 | 30K | 30K | 53K | 84K | 76K |
Total Assets | 129.4K▲ 0% | 115.41M▲ 89092.5% | 9.33M▼ 91.9% | 5.26M▼ 43.7% | 2.86M▼ 45.5% | 7.21M▲ 152.0% | 4.6M▲ 0% |
Asset Turnover | - | - | - | - | - | - | 0.00x |
Asset Growth % | - | 89092.47% | -91.91% | -43.68% | -45.53% | 152.01% | 513.21% |
Total Current Liabilities | 29.4K | 348.58K | 1.61M | 2.2M | 3.52M | 2.76M | 4.06M |
Accounts Payable | 0 | 0 | 240K | 319K | 929K | 787K | 912K |
Days Payables Outstanding | - | - | - | - | - | - | 36.36K |
Short-Term Debt | 0 | 0 | 0 | 0 | 1M | 182K | 185K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 29.4K | 348.58K | 256K | 407K | 644K | 1.74M | 2.91M |
Current Ratio | 1.76x | 1.17x | 5.49x | 2.27x | 0.64x | 2.41x | 1.00x |
Quick Ratio | 1.76x | 1.17x | 5.49x | 2.27x | 0.64x | 2.41x | 1.00x |
Cash Conversion Cycle | - | - | - | - | - | - | - |
Total Non-Current Liabilities | 269.99K | 160.34K | 14.8M | 15.12M | 3.33M | 1.85M | 251K |
Long-Term Debt | 0 | 0 | 0 | 0 | 2.96M | 286K | 251K |
Capital Lease Obligations | 0 | 0 | 156K | 59K | 368K | 0 | 337K |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 269.99K | 160.34K | 14.65M | 15.06M | 0 | 1.57M | 0 |
Total Liabilities | 299.39K | 508.92K | 16.41M | 17.31M | 6.85M | 4.61M | 4.31M |
Total Debt | 0 | 0 | 271K | 171K | 4.49M | 468K | 436K |
Net Debt | -51.7K | -38.94K | -7.99M | -4.42M | 3.3M | -5.52M | -1.98M |
Debt / Equity | - | - | - | - | - | 0.18x | 1.50x |
Debt / EBITDA | - | - | - | - | - | 0.04x | 0.04x |
Net Debt / EBITDA | - | - | - | - | - | -0.47x | -0.19x |
Interest Coverage | - | - | -39.75x | -563.00x | -317.35x | -915.08x | -2150.17x |
Total Equity | -169.99K▲ 0% | 114.91M▲ 67695.3% | -7.08M▼ 106.2% | -12.06M▼ 70.3% | -3.99M▲ 66.9% | 2.6M▲ 165.3% | 291K▲ 0% |
Equity Growth % | - | 67695.3% | -106.16% | -70.31% | 66.91% | 165.25% | 429.68% |
Book Value per Share | -0.10 | 69.62 | -4.23 | -107.91 | -6.39 | 19.58 | 0.90 |
Total Shareholders' Equity | -169.99K | 114.91M | -10.66M | -15.48M | -3.99M | 2.6M | 291K |
Common Stock | 298 | 115M | 1K | 1K | 2K | 42K | 46K |
Retained Earnings | -195.86K | -951.08K | -21.87M | -26.81M | -43.25M | -55.17M | -57.9M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 3.59M | 3.42M | 0 | 0 | 0 |
SLXN Cash Flow Statement
Silexion Therapeutics Ltd. (SLXN) cash flow — operating, investing & free cash flow history
| Metric | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|
Cash from Operations | -75K | -1.41M | -3.33M | -4.53M | -8.4M | -10.82M | -12.01M |
Operating CF Margin % | - | - | - | - | - | - | - |
Operating CF Growth % | - | -1776.31% | -136.99% | -35.8% | -85.38% | -28.86% | -194.27% |
Net Income | -195.86K | -755.22K | -3.49M | -5.11M | -16.52M | -11.91M | -12.91M |
Depreciation & Amortization | 0 | 0 | 57K | 45K | 25K | 14K | 12K |
Stock-Based Compensation | 0 | 0 | 125K | 130K | 5.86M | 134K | 420K |
Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Cash Items | 0 | -182.34K | -268K | 317K | 3.82M | 344K | 305K |
Working Capital Changes | 120.86K | -469.68K | 239K | 87K | -1.58M | 601K | 161K |
Change in Receivables | 0 | 0 | -40K | 18K | 0 | 0 | 16K |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 0 | -38K | 79K | 610K | -40K | 232K |
Cash from Investing | 0 | 0 | -524K | 573K | -22K | -14K | -8K |
Capital Expenditures | 0 | 0 | -40K | -12K | -22K | -9K | -3K |
CapEx % of Revenue | - | - | - | - | - | - | - |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 78K | 0 | 0 | 0 |
Cash from Financing | 126.7K | 116.4M | 2.75M | 522K | 5.1M | 15.64M | 8.29M |
Debt Issued (Net) | 149.99K | 150.01K | 0 | 0 | -250K | -696K | 0 |
Equity Issued (Net) | -23.29K | 118.8M | 2.75M | 522K | 3.05M | 16.34M | 8.21M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | -2.55M | 3K | 0 | 2.3M | 0 | 83K |
Net Change in Cash | 51.7K▲ 0% | -12.76K▼ 124.7% | -1.77M▼ 13806.1% | -3.66M▼ 106.5% | -3.38M▲ 7.9% | 4.8M▲ 242.4% | -3.74M▲ 0% |
Free Cash Flow | -75K▲ 0% | -1.41M▼ 1776.3% | -3.38M▼ 139.8% | -4.54M▼ 34.5% | -8.42M▼ 85.4% | -10.83M▼ 28.6% | -12.02M▲ 0% |
FCF Margin % | - | - | - | - | - | - | - |
FCF Growth % | - | -1776.32% | -139.83% | -34.55% | -85.38% | -28.63% | -31.76% |
FCF per Share | -0.05 | -0.85 | -2.02 | -40.64 | -13.49 | -81.44 | -37.19 |
FCF Conversion (FCF/Net Income) | 0.38x | 1.86x | 1.04x | 0.92x | 0.51x | 0.91x | 0.93x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
SLXN Key Ratios
Silexion Therapeutics Ltd. (SLXN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|
Return on Equity (ROE) | -1.32% | -5.96% | - | - | -457.63% | -516.87% |
Return on Invested Capital (ROIC) | -1.23% | -5.8% | - | - | - | -523.6% |
Debt / Equity | - | - | - | - | 0.18x | 1.50x |
Interest Coverage | - | -39.75x | -563.00x | -317.35x | -915.08x | -2150.17x |
FCF Conversion | 1.86x | 1.04x | 0.92x | 0.51x | 0.91x | 0.93x |
Related:SLXN Dividend History·SLXN Revenue History·SLXN Price History·SLXN P/E History·SLXN Financial Ratios·SLXN Institutional Holders
SLXN SEC Filings & Documents
Silexion Therapeutics Ltd. (SLXN) SEC filings — annual & quarterly reports (10-K, 10-Q)
SLXN Frequently Asked Questions
Silexion Therapeutics Ltd. (SLXN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Silexion Therapeutics Ltd. (SLXN) grew revenue by 0.0% over the past year. Growth has been modest.
Silexion Therapeutics Ltd. (SLXN) reported a net loss of $12.9M for fiscal year 2025.
Dividend & Returns
Silexion Therapeutics Ltd. (SLXN) has a return on equity (ROE) of -457.6%. Negative ROE indicates the company is unprofitable.
Silexion Therapeutics Ltd. (SLXN) had negative free cash flow of $12.0M in fiscal year 2025, likely due to heavy capital investments.